{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065339","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.084682+00:00","generated_at":"2026-06-18T06:24:14.730472+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023","bullets":["Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.","Enrollment of 36 subjects triggers pre-planned interim analysis; results expected mid-2023.","Primary endpoints: safety (TEAEs) and objective response rate (ORR).","Company notes improved durable responses in PD-L1 low (CPS<20) patient subset.","Full study plans to enroll ~62 patients; pepinemab global rights held by Vaccinex."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065339","json":"https://secwatch.observer/filing/0001193125-23-065339.json","markdown":"https://secwatch.observer/filing/0001193125-23-065339.md","text":"https://secwatch.observer/filing/0001193125-23-065339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/0001193125-23-065339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/d471144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:24:14.730472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}